Results 1 to 10 of about 1,973 (199)

Effective management Alopecia totalis by Ayurveda – A case report [PDF]

Journal of Ayurveda and Integrative Medicine, 2023
Alopecia areata (AA) is a T-cell-mediated autoimmune illness characterized by intermittent, non-scarring hair loss, Alopecia totalis(AT) is a type of AA characterized by total hair loss on the face and scalp.
Shivanand B. Patil, Giramalla S. Patil, Vijay Patil   +2 more
doaj   +4 more sources

Case Report: A novel KRT74 variant in an eight-year-old boy with alopecia totalis successfully treated with baricitinib [PDF]

Frontiers in Medicine
Alopecia areata is an autoimmune condition characterized by non-scarring hair loss, with genetic factors playing a significant role in disease susceptibility.
Zhirong Yao, Zhao Jingjun, Yao Zhirong   +2 more
exaly   +4 more sources

A case of unusual comedogenesis in alopecia totalis [PDF]

Indian Dermatology Online Journal, 2022
Balkrishna P Nikam, Snehal S Shelke, Asma A Hussain, Varsha Jamale   +3 more
doaj   +4 more sources

Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series [PDF]

Reports
Background: Alopecia areata is an autoimmune disorder characterized by nonscarring hair loss, which can progress to alopecia totalis or universalis.
Waleed Alajroush, Huda Alrwebah, Abdulelah Alghamdi, Salam Alanazi, Saif Alagha, Sawsan Alharthi   +5 more
doaj   +2 more sources

Treatment outcomes and considerations for topical immunotherapy in patients with alopecia totalis and alopecia universalis [PDF]

Frontiers in Medicine
BackgroundAlopecia areata (AA) is a chronic immune-mediated disorder causing non-scarring hair loss. Severe forms like alopecia totalis (AT) and alopecia universalis (AU) pose therapeutic difficult situations.
Taiyo Hitaka, Sanehito Haruyama, Shun Ohmori, Natsuko Saito-Sasaki, Etsuko Okada, Motonobu Nakamura, Yu Sawada   +6 more
doaj   +2 more sources

Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis. [PDF]

Cureus
Objectives Tofacitinib, an effective Janus kinase inhibitor (JAKi), has gained increasing interest in recent years for the management of refractory alopecia areata (AA). One of the most prevalent autoimmune diseases is AA, a kind of non-scarring alopecia.
Tirmizi SS, Ahmed MK, Iqbal T, Hashmi AA.   +3 more
europepmc   +3 more sources

The Role of Tofacitinib in the Management of Alopecia Totalis. [PDF]

Sultan Qaboos Univ Med J, 2019
Medical ...
Hernandez-Montoya C, Ruiz-Villaverde R.
europepmc   +5 more sources

Perceived Stress, Illness and Stigma in Patients with Alopecia Areata [PDF]

Acta Dermato-Venereologica
Alopecia areata is a nonscarring autoimmune hair loss disorder. Little is known about patients’ perceptions of their condition. This French cross-sectional online study primarily aimed to assess patients’ perception of stress as a causal factor, with ...
Maud Pellant, Laurent Misery, Anne-Sophie Ficheux, Khaled Ezzedine, Florian Stéphan, Claire Abasq-Thomas   +5 more
doaj   +2 more sources

Alopecia Totalis Treated with 1064 nm Picosecond Nd:YAG Laser: A Case Report

Applied Sciences (Switzerland), 2019
Alopecia areata (AA) is an autoimmune disorder causing nonscarring hair loss. Alopecia totalis (AT), the severe form of AA, is usually refractory to many first-line treatments including topical and intralesional corticosteroids and topical immunotherapy.
Ching-Chi Chi, Tzu-Yu Wang, Tsung-Hua Tsai   +2 more
exaly   +3 more sources

Association between alopecia areata and cardiovascular disease: a systematic review and meta-analysis [PDF]

Frontiers in Immunology
BackgroundAlopecia areata (AA) is a common autoimmune disorder causing patchy hair loss. Epidemiological observations and molecular studies collectively suggest an underrecognized interplay between AA and cardiovascular disease (CVD).
Jiawei Lu, Xuechen Cao, Yifei Feng, Yongkai Yu, Yan Lu   +4 more
doaj   +2 more sources